BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Semaglutide: trial readouts and FDA decisions
3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 9 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Novo Nordisk A/S, Skye Bioscience, Inc., Guangdong Raynovent Biotech Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Eccogene, Gan & Lee Pharmaceuticals., Eli Lilly and Company, Fujian Shengdi Pharmaceutical Co., Ltd.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-20 est. | P2 | Skye Bioscience, Inc. SKYE | NCT06577090 Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo | Obesity | active not recruiting | 136 |
| 2026-12-01 est. | P3 | Guangdong Raynovent Biotech Co., Ltd | NCT07139548 A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes | T2DM | not yet recruiting | 600 |
| 2026-12-31 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06884293 A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | active not recruiting | 479 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-15 est. | P2 | Eccogene | NCT07505303 MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial | Adult Obesity; Weight Management | active not recruiting | 151 |
| 2026-09-18 | P3 | Gan & Lee Pharmaceuticals. | NCT06778967 A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus (T2DM) | completed | 1133 |
| 2026-09-01 est. | P2 | Novo Nordisk A/S NVO | NCT06717698 A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease | Chronic Kidney Disease | recruiting | 465 |
| 2026-08-27 | P3 | Eli Lilly and Company LLY | NCT06260722 Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 | Diabetes Mellitus, Type 2 | active not recruiting | 1250 |
| 2026-07-18 | P3 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT06649344 A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 | Type 2 Diabetes | completed | 884 |
| 2026-06-29 | P3 | Novo Nordisk A/S NVO | NCT07271251 A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People Wi | Type 2 Diabetes | completed | 267 |
| 2026-06-16 | P2 | Regeneron Pharmaceuticals REGN | NCT06299098 A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weig | Obesity | completed | 1005 |
| 2026-06-02 | P3 | Novo Nordisk A/S NVO | NCT06534411 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGL | Diabetes Mellitus, Type 2 | completed | 1023 |
| 2026-05-30 est. | P3 | Hangzhou Jiuyuan Gene Engineering Co. Ltd., | NCT06633783 A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy® | Obesity | unknown | 370 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.